Essex Savings Bank’s Core Laboratories CLB Stock Holding History

Essex Savings Bank’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-312	Closed	-$16K	–	257
2019 Q2	$16K	Buy	312 +172	+123%	+$10.1K	0.01%	600
2019 Q1	$10K	Hold	140	–	–	0.01%	501
2018 Q4	$8K	Buy	+140	New	+$12.1K	0.01%	526

Other funds holding CLB

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Essex Savings Bank's CLB Position: Q3 2019 in Review

Essex Savings Bank sold out of Core Laboratories (CLB) in Q3 2019, closing a stake of 312 shares — an estimated $16K sold.

Essex Savings Bank first reported a position in CLB in Q4 2018 and held it in 3 quarters. The position peaked at $16K in Q2 2019. 274 funds tracked by Wall St. Rank hold CLB as of Q3 2019.

Essex Savings Bank reported no remaining Core Laboratories position as of Q3 2019 after selling out during the quarter.
Essex Savings Bank sold 312 Core Laboratories shares in Q3 2019, an estimated $16K.
Essex Savings Bank first reported a position in Core Laboratories in Q4 2018 and held it in 3 quarters.
Essex Savings Bank's Core Laboratories position peaked at $16K in Q2 2019.
274 funds tracked by Wall St. Rank held Core Laboratories as of Q3 2019.

Based on Essex Savings Bank's 13F filing for Q3 2019, filed 30 Oct 2019.